Unknown

Dataset Information

0

De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer.


ABSTRACT: Current adjuvant treatment guidelines for oropharyngeal squamous cell carcinoma treated with primary surgery are based on studies that predate the human papillomavirus (HPV) era. HPV-associated oropharynx carcinoma (HPV-OPC) has a much more favorable prognosis compared to HPV-unassociated cancer and is increasingly considered to be a distinct disease entity due to its unique etiology, presentation, and behavior. Currently, there is significant interest in adjuvant treatment de-intensification of HPV-OPC patients in order to reduce treatment-related toxicity while maintaining excellent clinical outcomes. Here, we review the evidence and rationale underlying the ongoing prospective trials of adjuvant treatment de-intensification for HPV-OPC patients.

SUBMITTER: An Y 

PROVIDER: S-EPMC6460758 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6189290 | BioStudies
2016-01-01 | S-EPMC5734050 | BioStudies
2018-01-01 | S-EPMC6065203 | BioStudies
2020-01-01 | S-EPMC7023689 | BioStudies
2019-01-01 | S-EPMC6779788 | BioStudies
2019-01-01 | S-EPMC6495356 | BioStudies
2018-01-01 | S-EPMC6204434 | BioStudies
2020-01-01 | S-EPMC7369227 | BioStudies
2016-01-01 | S-EPMC4754145 | BioStudies
2018-01-01 | S-EPMC5903634 | BioStudies